Schrodinger Inc. (SDGR) News

Schrodinger Inc. (SDGR): $26.96

0.33 (+1.24%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add SDGR to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#64 of 65

in industry

Filter SDGR News Items

SDGR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SDGR News Highlights

  • For SDGR, its 30 day story count is now at 5.
  • Over the past 13 days, the trend for SDGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG are the most mentioned tickers in articles about SDGR.

Latest SDGR News From Around the Web

Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, December 19, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. These grants were

Yahoo | December 19, 2023

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event

NEW YORK, December 14, 2023--Schrödinger is providing a detailed review of its proprietary drug discovery and development programs during its Pipeline Day.

Yahoo | December 14, 2023

Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry

Companies are applying AI in healthcare which is leading to better outcomes and stronger performance for their stocks.

Alex Sirois on InvestorPlace | December 11, 2023

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

NEW YORK, December 10, 2023--Schrödinger today announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor.

Yahoo | December 10, 2023

Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November

The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions.

TalkMarkets.com | December 6, 2023

3 Cutting-Edge Biotech Stocks for the Bold Investor

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks.

Josh Enomoto on InvestorPlace | November 14, 2023

AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence

We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare.

Ian Cooper on InvestorPlace | November 10, 2023

Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK, November 06, 2023--Schrödinger today announced that management will participate in two conferences in November.

Yahoo | November 6, 2023

3 Top Publicly Traded Companies Leading the AI Revolution

With recent data indicating AI is saving companies loads of money, three AI stocks to buy are exploiting this trend.

Larry Ramer on InvestorPlace | November 4, 2023

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2023 Earnings Call Transcript November 1, 2023 Schrödinger, Inc. misses on earnings expectations. Reported EPS is $-0.86 EPS, expectations were $-0.69. Operator: Welcome to Schrödinger’s Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today’s call. All lines have been […]

Yahoo | November 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!